

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
30 July 2020 (30.07.2020)



(10) International Publication Number
WO 2020/154268 A2

(51) International Patent Classification:

C12N 15/113 (2010.01) A61K 31/7088 (2006.01)
C07K 14/515 (2006.01) A61P 27/06 (2006.01)
C12Q 1/6827 (2018.01)

(21) International Application Number:

PCT/US2020/014373

(22) International Filing Date:

21 January 2020 (21.01.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/795,665	23 January 2019 (23.01.2019)	US
62/880,609	30 July 2019 (30.07.2019)	US
62/902,683	19 September 2019 (19.09.2019)	US
62/909,573	02 October 2019 (02.10.2019)	US

(71) Applicant: **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(72) Inventors: **PRAVEEN, Kavita**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **SCHURMANN, Claudia**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **GURSKI, Lauren**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **DOSTAL, Tanya Teslovich**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **ABECASIS, Goncalo**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **BARAS, Aris**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **COPPOLA, Giovanni**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(74) Agent: **LEGAARD, Paul K.**; Stradley Ronon Stevens & Young, LLP, 30 Valley Stream Parkway, Malvern, Pennsylvania 19355-1481 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))

WO 2020/154268 A2

(54) Title: TREATMENT OF OPHTHALMIC CONDITIONS WITH ANGIOPOIETIN-LIKE 7 (ANGPTL7) INHIBITORS

(57) Abstract: The present disclosure provides methods of treating patients having an ophthalmic condition, methods of identifying subjects having an increased risk of developing an ophthalmic condition, methods of detecting human angiotensinogen-like 7 (ANGPTL7) variant nucleic acid molecules and variant polypeptides, and ANGPTL7 variant nucleic acid molecules and variant polypeptides.